Stockscreener 앱 받기
95.93
1.73%
1.63
전일 마감가:
$94.30
열려 있는:
$93.02
하루 거래량:
1.16M
Relative Volume:
0.63
시가총액:
$19.09B
수익:
$5.14B
순이익/손실:
$1.29B
주가수익비율:
14.98
EPS:
6.4034
순현금흐름:
$1.33B
1주 성능:
+3.98%
1개월 성능:
-4.11%
6개월 성능:
+11.18%
1년 성능:
+53.91%
1일 변동 폭
$92.55
$96.05
1주일 범위
$90.08
$96.05
52주 변동 폭
$53.56
$112.29
인사이트 코퍼레이션 Stock (INCY) Company Profile
명칭
Incyte Corp
전화
(302) 498-6700
주소
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Compare INCY vs VRTX, REGN, ARGX, ALNY, INSM
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
95.93 | 19.09B | 5.14B | 1.29B | 1.33B | 6.4034 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
인사이트 코퍼레이션 Stock (INCY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2026-02-05 | 개시 | H.C. Wainwright | Buy |
| 2026-01-20 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-12-08 | 업그레이드 | Mizuho | Neutral → Outperform |
| 2025-11-03 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2025-10-08 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2025-08-06 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2025-08-01 | 개시 | Barclays | Overweight |
| 2025-06-16 | 업그레이드 | Stifel | Hold → Buy |
| 2025-03-18 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2025-03-18 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2024-12-17 | 개시 | UBS | Neutral |
| 2024-10-29 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-10-01 | 개시 | Wolfe Research | Outperform |
| 2024-09-18 | 다운그레이드 | Truist | Buy → Hold |
| 2024-07-02 | 다운그레이드 | BMO Capital Markets | Market Perform → Underperform |
| 2024-05-23 | 개시 | Deutsche Bank | Hold |
| 2024-04-23 | 개시 | Cantor Fitzgerald | Neutral |
| 2024-02-23 | 개시 | Jefferies | Buy |
| 2024-02-14 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-13 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2023-12-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-11-21 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-07-25 | 개시 | Citigroup | Buy |
| 2023-05-04 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-04-10 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-03-24 | 업그레이드 | SVB Securities | Underperform → Market Perform |
| 2023-01-31 | 개시 | Piper Sandler | Overweight |
| 2022-08-03 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-08-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-07-28 | 개시 | Wells Fargo | Equal Weight |
| 2022-02-09 | 다운그레이드 | SVB Leerink | Mkt Perform → Underperform |
| 2022-01-18 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-19 | 개시 | BMO Capital Markets | Market Perform |
| 2021-07-20 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2021-02-10 | 다운그레이드 | SVB Leerink | Mkt Perform → Underperform |
| 2021-01-07 | 개시 | Truist | Buy |
| 2021-01-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-06-16 | 개시 | The Benchmark Company | Hold |
| 2020-05-06 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-04-29 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-01 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-24 | 재개 | William Blair | Outperform |
| 2020-03-13 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2020-02-04 | 재개 | BofA/Merrill | Neutral |
| 2020-01-03 | 재확인 | BMO Capital Markets | Market Perform |
| 2020-01-03 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2020-01-02 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-10-03 | 개시 | Mizuho | Buy |
| 2019-09-12 | 개시 | BMO Capital Markets | Market Perform |
| 2019-09-05 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-09-05 | 재개 | Morgan Stanley | Equal-Weight |
| 2019-09-05 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2019-05-21 | 개시 | Credit Suisse | Neutral |
| 2019-05-03 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2019-04-11 | 개시 | Stifel | Hold |
| 2019-04-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-01-24 | 업그레이드 | William Blair | Mkt Perform → Outperform |
모두보기
인사이트 코퍼레이션 주식(INCY)의 최신 뉴스
Adagene reveals Incyte deal, data update and public offering - The Pharma Letter
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC) - Yahoo Finance
Citizens reiterates Incyte stock rating on pipeline progress - Investing.com
J. Safra Sarasin Holding AG Decreases Stake in Incyte Corporation $INCY - MarketBeat
Barclays Maintains Overweight on Incyte (INCY) Mar 2026 - Meyka
Incyte Corp. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Incyte Corp (INCY) Price Target Hiked at UBS on Sales and Earnings Growth Prospects - MSN
Incyte Corporation (INCY) Announces Board Member Resignation - GuruFocus
Incyte board member Susanne Schaffert to step down in April By Investing.com - Investing.com India
Incyte board member Susanne Schaffert to step down in April - Investing.com
Incyte's Susanne Schaffert to Resign from Board Effective April 15, 2026 - TradingView
INCY: HC Wainwright & Co. Reiterates 'Buy' Rating and $135 Price Target | INCY Stock News - GuruFocus
Incyte Shares Positive 54-Week Results From Advanced Skin Condition Trial - Bitget
Incyte Reports Strong 54-Week Data From Late-Stage Skin Disorder Study - Yahoo Finance
William Blair reiterates Market Perform on Incyte stock after HS data - Investing.com Canada
MoonLake and Incyte progress HS prospects at AAD - The Pharma Letter
Stifel reiterates Incyte stock rating on hidradenitis drug data By Investing.com - Investing.com India
Stifel reiterates Incyte stock rating on hidradenitis drug data - Investing.com
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack - Yahoo Finance
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting - Yahoo Finance
(INCY.O) | Stock Price & Latest News - Reuters
Incyte Corporation $INCY Shares Purchased by SG Americas Securities LLC - MarketBeat
Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch
Vanguard disaggregates holdings; reports 0% in Incyte (INCY) - Stock Titan
INCY Technical Analysis | Trend, Signals & Chart Patterns | INCYTE CORP (NASDAQ:INCY) - chartmill.com
Incyte Corporation (INCY) Announces Executive Leadership Title C - GuruFocus
Incyte Announces Key Executive Leadership Changes and Integration of U.S. Commercial Teams for Long-Term Growth - minichart.com.sg
INCYTE (NASDAQ: INCY) EVP sees 537 shares withheld to cover RSU taxes - Stock Titan
Pablo J. Cagnoni named President at Incyte; William J. Meury remains CEO - TradingView
Incyte (NASDAQ: INCY) appoints new President and consolidates U.S. commercial - Stock Titan
UBS Lowers Price Target for Incyte (INCY) While Maintaining Neut - GuruFocus
Barclays Maintains Overweight on INCY Incyte Corporation March 2026 - Meyka
Incyte Corp. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Incyte Appoints Three to Executive Leadership Positions - Contract Pharma
UBS lowers Incyte stock price target on revenue concerns to $94 - Investing.com Australia
UBS Group Lowers Incyte (NASDAQ:INCY) Price Target to $94.00 - marketbeat.com
KPTI Stock Down on Mixed Phase III Myelofibrosis Combo Study Data - Yahoo! Finance Canada
Incyte announces executive leadership changes, integrates U.S. teams - Investing.com
Incyte Announces Executive Leadership Appointments - Business Wire
H.C. Wainwright reiterates Incyte stock rating citing oral drug potential - Investing.com
HC Wainwright Reiterates Buy Rating for Incyte (INCY) | INCY Sto - GuruFocus
A Look At Incyte (INCY) Valuation After Mixed Short Term Returns And Strong One Year Performance - Yahoo Finance
Barclays reiterates Incyte stock rating after mixed trial results - Investing.com
Barclays reiterates Incyte stock rating after mixed trial results By Investing.com - Investing.com UK
Nordea Investment Management AB Acquires 291,293 Shares of Incyte Corporation $INCY - MarketBeat
Chronic Hand Eczema Pipeline 2026: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Incyte Corp, LEO Pharma, Asana BioSciences, Arcutis Biotherapeutics, Innovaderm Research - Barchart.com
Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting - BioSpace
Swiss Life Asset Management Ltd Increases Stake in Incyte Corporation $INCY - MarketBeat
New England Research & Management Inc. Acquires New Stake in Incyte Corporation $INCY - MarketBeat
Incyte Corporation $INCY Shares Sold by JPMorgan Chase & Co. - marketbeat.com
인사이트 코퍼레이션 (INCY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.49%
1.47%
자본화:
|
볼륨(24시간):